A 48-year-old man comes to the clinic for a routine follow-up visit. Three weeks ago, he w… — USMLE Step 3

A $48$ -year-old man comes to the clinic for a routine follow-up visit. Three weeks ago, he was diagnosed with active, smear-positive pulmonary tuberculosis and was started on a daily induction regimen of isoniazid, rifampin, pyrazinamide, and ethambutol, along with pyridoxine. Today, he reports that his initial cough has significantly improved and he has not had a fever or night sweats for the past week. He feels well and specifically denies fatigue, anorexia, nausea, vomiting, dark urine, or abdominal pain. He has a history of latent tuberculosis $15$ years ago for which he did not complete treatment. He takes no other medications and does not consume alcohol. Vital signs are within normal limits. Physical examination reveals no scleral icterus, right upper quadrant tenderness, or hepatomegaly.

Laboratory studies obtained today (Week 3) compared to baseline (Week 0) are as follows:

Parameter	Week 0 (Baseline)	Week 3 (Today)	Reference Range
Total bilirubin	$0.8$ mg/dL	$1.0$ mg/dL	$0.1$ - $1.2$ mg/dL
Aspartate aminotransferase (AST)	$22$ U/L	$138$ U/L	$8$ - $40$ U/L
Alanine aminotransferase (ALT)	$28$ U/L	$152$ U/L	$10$ - $40$ U/L
Alkaline phosphatase	$85$ U/L	$92$ U/L	$40$ - $120$ U/L

Which of the following is the most appropriate next step in the management of this patient?

Continue the current medication regimen and repeat laboratory testing in one weekAnswer
B
Discontinue isoniazid, rifampin, and pyrazinamide until transaminases normalize
C
Discontinue pyrazinamide only and maintain the remainder of the regimen
D
Obtain a right upper quadrant abdominal ultrasound
E
Substitute a fluoroquinolone for isoniazid and continue the other medications

Answer

Continue the current medication regimen and repeat laboratory testing in one week

The correct action is to continue the current medication regimen and monitor closely. Mild, asymptomatic elevation in hepatic transaminases is a common and expected pharmacologic effect during the initial weeks of treatment with isoniazid, rifampin, and pyrazinamide (which are all potentially hepatotoxic). According to clinical guidelines, these medications should be stopped only if transaminases rise to greater than 3 times the upper limit of normal in a patient with symptoms of clinical hepatitis (e.g., nausea, vomiting, right upper quadrant pain, jaundice, profound fatigue), or if they rise to greater than 5 times the upper limit of normal in an asymptomatic patient. This patient is completely asymptomatic, and his AST and ALT are approximately 3.5 and 3.8 times the upper limit of normal, respectively. Because the 5 times upper limit of normal threshold has not been reached, discontinuing or altering the medications is inappropriate. The best approach is careful surveillance with repeat liver chemistries in one week.

Step-by-Step Solution

Analyze the patient's clinical presentation.

The patient is entirely asymptomatic, specifically denying signs of clinical hepatitis such as nausea, vomiting, abdominal pain, jaundice, and fatigue.

Determining the presence or absence of symptoms is critical for applying toxicity management algorithms.

Evaluate the laboratory values in the context of reference ranges.

AST is 138 U/L (approximately 3.5 times the upper limit of normal) and ALT is 152 U/L (approximately 3.8 times the upper limit of normal). Total bilirubin and alkaline phosphatase remain normal.

Quantifying the degree of transaminase elevation determines whether the toxicity threshold has been crossed.

Apply established monitoring guidelines for antituberculous therapy.

Guidelines dictate that hepatotoxic drugs (isoniazid, rifampin, pyrazinamide) should only be discontinued if transaminases exceed 3 times the upper limit of normal in the presence of symptoms, or if they exceed 5 times the upper limit of normal in the absence of symptoms.

These established thresholds balance the risk of severe drug-induced liver injury against the risk of tuberculosis treatment failure.

Determine the appropriate management intervention.

Since the patient is asymptomatic and transaminases are less than 5 times the upper limit of normal, the current regimen should be continued without alteration, accompanied by close serial monitoring.

Mild, asymptomatic transaminitis is a common and often transient expected effect of induction therapy.

Key Concept

Management of antituberculous drug-induced hepatotoxicity based on symptom correlation and enzymatic thresholds.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic